TELA Bio, Inc. has appointed Heather Getz as its new CEO, effective today, following the resignation of Antony Koblish. This leadership shift is critical for investors as Getz brings over 25 years of experience in healthcare, likely impacting company strategy and growth opportunities moving forward.
Key Highlights
- Heather Getz appointed as CEO effective August 3, 2026.
- Getz's employment agreement includes an annual base salary of $650,000.
- TELA Bio shares have dropped 28.9% year-to-date despite a recent monthly gain of 3.1%.
Leadership change is significant at TELA Bio, Inc. (NASDAQ: TELA) as Heather Getz steps in as the new Chief Executive Officer, effective today. This transition follows the resignation of Antony Koblish, who has held the position since the company’s inception. The switch comes at a important time for TELA, reflecting both strategic realignment and an opportunity for rejuvenation after a disappointing 28.9% drop in share price this year, which has drawn investor scrutiny.
Transition Details
Antony Koblish's departure marks the ninth leadership change at TELA since August 2022. Getz, who has an extensive background in the healthcare sector, replaces Koblish, whose resignation was not due to disagreement over the company's operations. This change is positioned as a calculated move to refocus the company's direction and enhance its operational effectiveness in a competitive environment.
Investors will be interested in how this executive shift could lead to new strategies aimed at reversing the company's year-to-date performance declines.
Getz's Impressive Background
Heather Getz brings over 25 years of experience in the healthcare sector, having successfully driven growth and value creation in her previous roles. She was key in transforming BioTelemetry, Inc. where market capitalization surged from $50 million to $2.8 billion before its acquisition by Koninklijke Philips N.V. In 2021. During her tenure, Getz demonstrated a strong capability in financial leadership, having secured over $1 billion in financing and integrated more than 40 companies.
Her proven track record may restore confidence among investors as she steps into this new role, and her strategic acumen will be vital for TELA Bio's upcoming initiatives.
Significance of the Timing
The company’s current market capitalization stands at approximately $33 million, presenting both risks and opportunities. Sector peers like UTMD are also down, indicating broader market pressures, while EMBC shows resilience with a 3.1% increase today. Investors will likely scrutinize the company’s strategic roadmap and financial execution under Getz’s leadership to identify how her vision may turn around TELA's performance.
What’s Ahead for TELA Bio
Looking forward, TELA will hold its 2027 Annual Meeting, where more strategic updates and potential shifts in corporate governance may be discussed. Investors will pay close attention to how Heather Getz articulates her vision for the company's future and the operational strategies she intends to implement. This meeting will provide important insights into how TELA Bio plans to reclaim market confidence and enhance shareholder value in the months to come.
The immediate focus will be on her plans and how quickly they can translate into tangible improvements in both operational performance and investor sentiment.
Peers Moving on This News
- Utah Medical Products Inc (UTMD) down 0.8%
- Embecta Corp (EMBC) up 3.1%
- Acme United Corp (ACU) down 2.2%
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...